2.07 USD
▲-0.05+5.08%
盘后 2.00 +1.52%
2026-08-03
市值
$130.34M
市盈率
—
EPS
-1.16
股息率
—
52 周区间
1.23 – 3.82
成交量
267.72K
Beta
-0.18
目标价
7.13
52W 低 1.2352W 高 3.82
价格走势
公司简介
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Rα in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.